Obsidian Therapeutics, Inc. announced that two abstracts highlighting preclinical data on the use of its technology for regulation of immunocytokines have been selected for presentation at the 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place May 16-19, 2018, in Chicago, IL.
Details of the poster presentations, both taking place on Wednesday, May 16, 2018, are as follows:
| Poster Title: | Exogenous In Vitro and In Vivo Regulation of Interleukin-12 Secretion from T Cells Using Destabilizing Domain Technology | ||||
| Presenter: | Dexue Sun | ||||
| Session Date/Time: | Wednesday, May 16, 2018, at 5:30 - 7:30 p.m. CT | ||||
| Session title: | Cancer - Immunotherapy, Cancer Vaccines I | ||||
| Room: | Stevens Salon C, D | ||||
| Abstract number: | 113 | ||||
| Poster Title: | Dose dependent exogenous regulation of membrane bound Interleukin-15-Interleukin-15 receptor alpha fusion protein for adoptive T-cell therapy | ||||
| Presenter: | Christopher Reardon | ||||
| Session Date/Time: | Wednesday, May 16, 2018, at 5:30 - 7:30 p.m. CT | ||||
| Session title: | Cancer - Targeted Gene & Cell Therapy I | ||||
| Room: | Stevens Salon C, D | ||||
| Abstract number: | 133 | ||||
About Destabilizing Domains
Obsidian uses Destabilizing Domains (DDs) to enable pharmacologic regulation of protein activity for next-generation cell and gene therapies. Obsidian’s DDs are small, fully-human protein domains that confer conditional stability to a fused payload protein. In the absence of a specific small molecule ligand the fusion protein is rapidly degraded, whereas in the presence of the ligand, the fusion protein becomes stable and functional. Obsidian uses this approach to equip engineered cells with controllable functions that can be precisely tuned by the administration of non-immunosuppressive, small molecule medicines that are readily available and dispensed by the treating physician.
About Obsidian Therapeutics
Obsidian Therapeutics is a biotechnology company developing next-generation cell and gene therapies with pharmacologic operating systems. Based upon founding work on destabilizing domains by Professor Thomas Wandless, a leading researcher in chemical and systems biology, Obsidian’s lead programs are CAR-T products that incorporate controllable functions for enhanced safety and efficacy. Obsidian was founded in 2015 by Atlas Venture and is funded by a strong syndicate of venture investors. The company is headquartered in Cambridge, Massachusetts. Please visit www.obsidiantx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180501005353/en/
Contacts
The Yates Network
Kathryn Morris, 914-204-6412
kathryn@theyatesnetwork.com
